Tofacitinib and faecal microbiota transplantation in treating checkpoint inhibitor-induced enterocolitis: case report
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › fagfællebedømt
Dokumenter
- Fulltest
Forlagets udgivne version, 1,3 MB, PDF-dokument
BACKGROUND: Immune checkpoint inhibitors (ICIs) can induce a wide range of immune-related adverse events (irAEs), potentially affecting any organ. ICI-induced colitis is a frequently reported irAE, whereas enteritis is rare and not well documented.
CASE PRESENTATION: We are presenting a patient with metastatic melanoma who developed severe ICI-induced enterocolitis multirefractory for glucocorticoids, infliximab and vedolizumab, partially responding to faecal microbiota transplantation and final complete response to tofacitinib.
CONCLUSION: This case supports that tofacitinib may be an(other) effective agent in managing multirefractory ICI-induced diarrhoea caused by colitis and/or enteritis.
Originalsprog | Engelsk |
---|---|
Artikelnummer | e000989 |
Tidsskrift | BMJ Open Gastroenterology |
Vol/bind | 9 |
Udgave nummer | 1 |
Antal sider | 4 |
ISSN | 2054-4774 |
DOI | |
Status | Udgivet - 2022 |
Bibliografisk note
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
ID: 333478308